Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma, Synovial 1 Sarcoma, Alveolar Soft Part 1 Sarcoma 1 Pancreatic Neoplasms 1 Medulloblastoma 1 Liver Cirrhosis 1 Leiomyosarcoma 1 Drug-drug Interaction,SHR3680 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Advanced Solid Malignancies 1 Advanced Pancreatic Cancer 1

Interventions

pembrolizumab 243 Carboplatin 211 Pemetrexed 177 Cisplatin 131 Paclitaxel 113 Nivolumab 101 Docetaxel 87 osimertinib 85 durvalumab 78 Specimen Handling 56 atezolizumab 55 Gemcitabine 52 Drug Therapy 52 Magnetic Resonance Spectroscopy 50 Radiosurgery 48 Radiotherapy 47 Ipilimumab 41 130-nm albumin-bound paclitaxel 39 cemiplimab 38 Bevacizumab 34 Cetuximab 30 tislelizumab 29 amivantamab 22 Taxes 22 Platinum Compounds 20 Blood Specimen Collection 20 Immunotherapy 18 Immune Checkpoint Inhibitors 18 Radiation 17 Erlotinib Hydrochloride 17

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Non-Small-Cell Lung × Digoxin × 1 year × Clear all

NCT06575933 2026-02-11

MK-1084-009

Merck Sharp & Dohme LLC

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡